MEI Pharma Inc: to Prioritize Clinical Development of Voruciclib While Enabling Development of a New Me-344 Formulation for Phase 1 Study
MEI Pharma Inc:优先考虑Voruciclib的临床开发,同时支持为1期研究开发新的ME-344配方
MEI Pharma Inc: to Prioritize Clinical Development of Voruciclib While Enabling Development of a New Me-344 Formulation for Phase 1 Study
MEI Pharma Inc:优先考虑Voruciclib的临床开发,同时支持为1期研究开发新的ME-344配方
使用浏览器的分享功能,分享给你的好友吧